Background: SARS-CoV-2 infection has been increasingly associated with post-infectious or immune-mediated neurological complications in children. Among these, optic neuritis is rare but clinically significant, as it can represent an isolated inflammatory event or the heralding episode of an underlying demyelinating disorder such as myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). COVID-19–related immune dysregulation may act as a trigger for autoimmune CNS disease through mechanisms of molecular mimicry, cytokine activation, or altered immune tolerance.
Case Presentation Summary: A 7-year-old previously healthy girl presented with acute, progressive bilateral visual loss over four days, two months after an asymptomatic SARS-CoV-2 infection. She had received a single COVID-19 vaccine dose before infection. Ophthalmologic assessment revealed bilateral optic disc swelling, severe reduction in visual acuity (1/10 OU), and impaired color perception. Brain MRI was normal; serum and CSF immunologic studies were negative. Visual evoked potentials were abnormal in the right optic nerve. High-dose intravenous methylprednisolone (IVMP) led to full recovery.
Eighteen months later, following another SARS-CoV-2 infection, she developed a second episode of subacute bilateral visual decline. Visual acuity was 7/10 + 1 OD and 5/10 + 1 OS. MRI showed nonspecific demyelinating lesions in the occipital horn of the right lateral ventricle, while bilateral visual evoked responses were again abnormal. No autoimmune antibodies were detected. IVMP therapy resulted in complete visual recovery.
Over four years of follow-up, imaging remained stable, and no new relapses occurred. At puberty, serum anti-MOG IgGantibodies became positive, confirming the diagnosis of MOG-antibody associated disease (MOGAD).
Learning Points Discussion
- Post-infectious immune activation by SARS-CoV-2 can precipitate CNS autoimmunity in children, including MOGAD, NMOSD, and autoimmune encephalitis.
- Optic neuritis following COVID-19—especially when recurrent or bilateral—should prompt investigations for MOG and AQP4 antibodies, even if initial immunologic and imaging studies are normal.
- MOGAD accounts for nearly one-third of pediatric acquired demyelinating syndromes and often presents with optic neuritis in older children.
- Long-term monitoring with MRI and antibody testing is essential, as seroconversion may occur years after the first demyelinating event.
- The case reinforces accumulating evidence that COVID-19 may act as a trigger for autoimmune diseases in children, potentially unmasking latent immune susceptibilities affecting the CNS. Awareness of this temporal association is crucial for early recognition and management.
- High-dose corticosteroids remain first-line therapy for acute episodes, with favorable visual and neurological outcomes in most pediatric cases.

